Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Bayer Eyes 2026 Launch for Sevabertinib under “3-Plus-3” Strategy in Japan
Quick Look: Bayer Japan aims to continue growing Kerendia, Nubeqa, and Eylea 8 mg after the three key brands logged double- or triple-digit gains in 2025. Approval-pending sevabertinib is set for a 2026 launch, with two more PIII assets —…
To read the full story
Related Article
BUSINESS
- Viatris Recalls Sevoflurane Anesthetic over Manufacturing Deviation
August 3, 2026
- Belite Bio Japan Launches Stargardt Disease Awareness Initiative
August 3, 2026
- Otsuka Eyes 3.5 Trillion Yen Sales by 2035 on New Growth Drivers
August 3, 2026
- Daiichi Sankyo Cuts FY2027 Net Profit Outlook on Higher Tax Burden
August 3, 2026
- Kissei Slashes Tavneos Sales Forecast after Safety, Data Concerns
August 3, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…